Relationship Between β Adrenoceptor Occupancy and Receptor Down-Regulation Induced β Antagonists with Intrinsic Sympathomimetic Activity

References

• Su YF, Harden TK, Perkins JP. Isoproterenol-induced desensitization of adenylate cyclase in human astrocytoma cells. J Biol Chem. 1979; 254: 38–41
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of β-adrenergic receptor function. FASEB J 1990; 4: 2881–2889
   PubMed Web of Science ®Google Scholar
• Hadcock JR, Malbon CC. Down-regulation of β-adrenergic receptors: Agonist-induced reduction in receptor of mRNA levels. Proc Natl Acad Sci 1988; 85: 5021–5025
   PubMed Web of Science ®Google Scholar
• Bouvier M, Collins S, O'Dowd BF, Campbell PT, Deblasi A, Kobilka BK, MacGregor C, Irons GP, Caron MG, Lefkowitz RJ. Two distinct pathways for cAMP-mediated down-regulation of the β-adrenergic receptor. J Biol Chem 1989; 264: 16786–16792
   PubMed Web of Science ®Google Scholar
• Hadcock JR, Wang HY, Malbon CC. Agonist-induced destabilization of β-adrenergic receptor mRNA. J Biol Chem 1989; 264: 19928–19933
   Google Scholar
• Hadcock JR, Ros M, Malbon CC. Agonist regulation of β-adrenergic receptor mRNA. J Biologic Chem 1989; 264: 13956–13961
   Google Scholar
• Port JD, Huang LY, Malbon CC. β-Adrenergic agonists that down-regulate receptor mRNA up-regulate a Mr35,000 protein(s) that selectively binds to β-adrenergic receptor mRNAs. J Biol Chem 1992; 267: 24103–24108
   PubMed Web of Science ®Google Scholar
• Pittman RN, Molinoff PB. Interactions of full and partial agonists with β- adrenergic receptors on intact L6 muscle cells. Mol Pharmacol. 1983; 24: 398–408
   Google Scholar
• Frishman WH. Adrenergic receptors as pharmacological targets: the beta adrenergic blocking drugs. Adrenergic Receptors in Man, P Insel 1987; 69–119, marcel dekker, inc., new
   Google Scholar
• Neve KA, Barrett DA, Molinoff PB. Selective regulation of beta-1 and beta-2 adrenergic receptors by atypical agonists. J Pharmacol Exp Ther 1985; 235: 657–664
   Google Scholar
• Reynolds EE, Molinoff PB. Down regulation of beta adrenergic receptors in S49 lymphoma cells induced by atypical agonists. J Pharmacol Exp Ther. 1986; 239: 654–660
   Google Scholar
• Kaumann AJ, Blinks JR. β-Adrenoceptor blocking agents as partial agonists in isolated heart muscle. Naunyn-Schmiedebergs Arch. Pharmacol 1980; 311: 237–248
   Google Scholar
• Walter M, Lemoine H, Kaumann AJ. Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of β-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn-Schmiedeberg's Arch Pharmacol. 1984; 327: 159–175
   Google Scholar
• Kaumann AJ, Lemoine H, Schwederski-Menke U, Ehle B. Relations between β-adrenoceoptor occupancy and increases in contractile force and adenylate cyclase activity induced by catecholamines in human ventricular myocardium. Naunyn-Schmiedeberg's Arch Pharmacol. 1989; 339: 99–112
   Google Scholar
• Kaumann AJ. Is there a third heart β-adrenoceptor?. TiPS. 1989; 10: 316–320
   Google Scholar
• Golf S, Hansson V. Relative potencies of various β-adrenoceptor antagonists (BAA) at the level of the human myocardial β-adrenoceptor- adenylate cyclase (AC) complex: is intrinsic sympathomimetic activity (ISA) due to AC activation?. Scand J Clin Lab Invest 1986; 46: 121–130
   PubMed Web of Science ®Google Scholar
• Golf S, Hansson V. Effects of full and partial agonists and antagonists upon β-receptor occupancy and adenylate cyclase activation in human myocardial membrane preparations. J Cardiovas Pharmacol 1987; 10(Suppl.4)S120–S121
   Google Scholar
• Michel MC, Wang XL, Daul A, Brodde O -E. β-adrenoceptor antagonists with intrinsic sympathomimetic activity downregulate human lymphocyte β-adrenoceptor density but do not activate the lymphocyte cyclic AMP system. J Cardiovasc Pharmacol. 1987; 10(suppl. 4)s117–s119
   Google Scholar
• Jasper JR, Michel MC, Insel PA. Molecular mechanism of β-adrenergic receptor blockers with intrinsic sympathomimetic activity. FASEB J., 2: 2891–2894
   Google Scholar
• Jasper JR, Michel MC, Insel PA. Amplification of cyclic AMP generation reveals agonistic effects of certain β-adrenergic antagonists. Mol Pharmacol. 1989; 37: 44–49
   Google Scholar
• Cruickshank JM. Measurement and cardiovascular relevance of partial agonist activity (PAA) involving β1- and β2-adrenoceptors. Pharmac Ther. 1990; 46: 199–242
   PubMed Web of Science ®Google Scholar
• Manin't Veld AJ., Van den Meiracker AH. Pindolol. Cardiovascular Drug Therapy, Messerli FH. W.B. Saunders Company, Philadelphia 1990; 471–484
   Google Scholar
• Ochi S, Nakazawa M, Kimura T, Nakagawa Y, Imai S. Partial agonist activity of celiprolol, a cardioselective β-antagonist. Eur J Pharmacol. 1991; 194: 1–5
   Google Scholar
• Engel G, Hoyer D, Berthold R, Wagner H. (+/-)125Iodo)cyanopindolol, a new ligand for β-adrenoceptors: identification and quantitation of subclasses of β adrenoceptors in guinea pig. Naunyn-Schmiedeberg's Arch Pharmacol. 1981; 317: 277–285
   Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randal RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Hill AV. The possible effects of the aggregation on the molecules of haemoglobin on its dissociation curves. J Physiol. 1910; 40: iv–vii
   Google Scholar
• Metzler CM, Elfring GL, McWren AJ. A package of computer programs for pharmacokinetic modeling. Biometrics 1984; 30: 562
   Google Scholar
• Cheng Y-C, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22: 3099–3108
   PubMed Web of Science ®Google Scholar
• Landaw E, Di Stefano JJ., III. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol. 246 1984; 15: R665–R677
   Google Scholar
• Monopoli A, Forlani M, Vago T, Norbiato G, Bertora P, Biglioli P, Alamanni F, Ongini E. Interaction of selected vasodilating β-blockers with adrenergic receptors in human cardiovascular tissues. J Cardiovas Pharmacol. 1989; 14: 114–120
   Google Scholar
• DeBlasi A, Fratelli M, Marasco O. Certain β-blockers can decrease β-adrenergic receptor number: I. Acute reduction in receptor number by tertatolol and bopindolol. Circ Res. 1988; 63: 273–278
   Google Scholar
• Hughes RJ, Mahan LC, Insel PA. Certain β-blockers can decrease β-adrenergic receptor number: II. Down-regulation of receptor number by alprenolol and propranolol in cultured lymphoma and muscle cells. Circ Res. 1988; 63: 279–285
   Google Scholar
• Krukemyer JJ, Boudoulas H, Binkley PF, Lima JJ. Relationship between lymphocyte β receptor density and physiologic response during and after propranolol and nadolol treatment. Pharmacol. 1990; 9: 385–391, (Life Sci Adv)
   Google Scholar
• Malbon CC, Hadcock JR, Rapiejko PJ, Ros M, Wang HY, Watkins DC. Regulation of transmembran signalling elements: transcriptional, post-transcriptional and post-translational controls. Biochem Soc Symp 1990; 56: 155–164
   Google Scholar
• Lohse MJ. Molecular mechanisms of membrane receptor desensitization. Biochimica et Biophysica. Acta. 1993; 1179: 171–188
   Google Scholar